Mesenchymal stem cell therapy in graft versus host disease

Shivaprasad Manjappa, Rizwan Romee, Armin Rashidi

Research output: Chapter in Book/Report/Conference proceedingChapter


Graft versus host disease (GVHD) is a common complication of allogeneic hematopoietic cell transplantion (HCT) and a major cause of posttransplant morbidity and mortality. Despite recent advancements in our knowledge regarding pathophysiology of GVHD, success in treatment has been limited. Mesenchymal stem cells (MSC) have immunomodulatory and antiinflammatory properties that can be exploited for the prevention and treatment of GVHD, with established preliminary results in early-phase clinical trials. In this chapter, we briefly review HCT and GVHD, and evaluate the evidence for MSC therapy in GVHD.

Original languageEnglish (US)
Title of host publicationA Roadmap to Nonhematopoietic Stem Cell-Based Therapeutics
Subtitle of host publicationFrom the Bench to the Clinic
Number of pages31
ISBN (Electronic)9780128119204
ISBN (Print)9780128119211
StatePublished - Jan 1 2018

Bibliographical note

Publisher Copyright:
© 2019 Elsevier Inc. All rights reserved.


  • Allogeneic HCT
  • Autologous HCT
  • Graft versus host disease
  • Hematopoietic cell transplantation
  • Mesenchymal stem cell
  • Syngeneic HCT


Dive into the research topics of 'Mesenchymal stem cell therapy in graft versus host disease'. Together they form a unique fingerprint.

Cite this